Compare ERC & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ERC | ELDN |
|---|---|---|
| Founded | 2003 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 259.5M | 208.6M |
| IPO Year | N/A | 2014 |
| Metric | ERC | ELDN |
|---|---|---|
| Price | $8.99 | $2.89 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 75.6K | ★ 1.1M |
| Earning Date | 01-01-0001 | 03-26-2026 |
| Dividend Yield | ★ 8.37% | N/A |
| EPS Growth | N/A | ★ 54.27 |
| EPS | ★ 0.72 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.49 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.65 | $1.35 |
| 52 Week High | $9.78 | $4.60 |
| Indicator | ERC | ELDN |
|---|---|---|
| Relative Strength Index (RSI) | 29.99 | 62.61 |
| Support Level | $8.90 | $2.48 |
| Resistance Level | $9.45 | $3.21 |
| Average True Range (ATR) | 0.09 | 0.21 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 9.18 | 65.75 |
Allspring Multi-Sector Income Fund is a closed-end investment management company. The company's core business is to secure a high level of income for its investors consistent with limiting its overall exposure to domestic interest rate risk. It invests in U.S. dollar-denominated below investment-grade bonds, debentures, and other income obligations, including loans and preferred stocks, developed and emerging market debt securities, including obligations of foreign governments or governmental entities, foreign corporations, or supranational agencies denominated in various currencies, asset backed securities and investment grade corporate bonds.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.